These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29750835)

  • 1. LRP1 Suppresses Bone Resorption in Mice by Inhibiting the RANKL-Stimulated NF-κB and p38 Pathways During Osteoclastogenesis.
    Lu D; Li J; Liu H; Foxa GE; Weaver K; Li J; Williams BO; Yang T
    J Bone Miner Res; 2018 Oct; 33(10):1773-1784. PubMed ID: 29750835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
    Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
    Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
    Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
    Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Water solution of onion crude powder inhibits RANKL-induced osteoclastogenesis through ERK, p38 and NF-kappaB pathways.
    Tang CH; Huang TH; Chang CS; Fu WM; Yang RS
    Osteoporos Int; 2009 Jan; 20(1):93-103. PubMed ID: 18506384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-κB and MAPKs signaling pathways.
    Liang S; Nian Z; Shi K
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1028-1035. PubMed ID: 32321638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways.
    Chen H; Fang C; Zhi X; Song S; Gu Y; Chen X; Cui J; Hu Y; Weng W; Zhou Q; Wang Y; Wang Y; Jiang H; Li X; Cao L; Chen X; Su J
    J Cell Mol Med; 2020 Aug; 24(16):9067-9084. PubMed ID: 32604472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation.
    Kong X; Wu W; Yang Y; Wan H; Li X; Zhong M; Zhao H; Su X; Jia S; Ju D; Lin N
    J Transl Med; 2015 Mar; 13():91. PubMed ID: 25889035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass.
    Mun SH; Won HY; Hernandez P; Aguila HL; Lee SK
    J Bone Miner Res; 2013 Apr; 28(4):948-59. PubMed ID: 23044992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corilagin suppresses RANKL-induced osteoclastogenesis and inhibits oestrogen deficiency-induced bone loss via the NF-κB and PI3K/AKT signalling pathways.
    Lu J; Ye C; Huang Y; Huang D; Tang L; Hou W; Kuang Z; Chen Y; Xiao S; Yishake M; He R
    J Cell Mol Med; 2020 Sep; 24(18):10444-10457. PubMed ID: 32681612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guaiacol suppresses osteoclastogenesis by blocking interactions of RANK with TRAF6 and C-Src and inhibiting NF-κB, MAPK and AKT pathways.
    Zhi X; Fang C; Gu Y; Chen H; Chen X; Cui J; Hu Y; Weng W; Zhou Q; Wang Y; Wang Y; Jiang H; Li X; Cao L; Chen X; Su J
    J Cell Mol Med; 2020 May; 24(9):5122-5134. PubMed ID: 32185887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.